Olufolarin Ajao, MD
Internal Medicine · Gastonia, NCNPI 1528059920
Payments from drug & device makers
Across 240 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$564
- AstraZeneca$551
- Novo Nordisk$501
- AbbVie$370
- Boehringer Ingelheim$277
- Astellas Pharma US Inc$234
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,96895%
- Education$2175%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 33 | $564 |
| AstraZeneca | 34 | $551 |
| Novo Nordisk | 32 | $501 |
| AbbVie | 20 | $370 |
| Boehringer Ingelheim | 18 | $277 |
| Astellas Pharma US Inc | 9 | $234 |
| Bayer | 12 | $191 |
| GSK | 12 | $184 |
| Merck | 8 | $147 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $109 |
| Pfizer | 6 | $93 |
| Amarin Pharma, Inc. | 5 | $76 |
| Amgen | 4 | $67 |
| Johnson & Johnson(2 entities) | 3 | $64 |
| Abbott | 3 | $59 |
| Esperion Therapeutics, Inc. | 4 | $56 |
| Paratek Pharmaceuticals, Inc. | 3 | $47 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Lundbeck LLC | 2 | $31 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| Boston Scientific | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Almatica Pharma LLC | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Novartis | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
| QOL Medical, LLC | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Scynexis, Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
How this compares
$4,186 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 217 | $281,201 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $101,820 |
| EliquisApixaban | 85 | $85,088 |
| TrulicityDulaglutide | 53 | $82,535 |
| JardianceEmpagliflozin | 79 | $79,516 |
| MounjaroTirzepatide | 57 | $77,947 |
| FarxigaDapagliflozin Propanediol | 57 | $65,942 |
| JanuviaSitagliptin Phosphate | 32 | $41,427 |
| LinzessLinaclotide | 50 | $38,973 |
| XifaxanRifaximin | 12 | $37,336 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $25,597 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $24,556 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 27 | $24,066 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $22,057 |
| RexultiBrexpiprazole | 14 | $21,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $501 | $299,930233 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $564 | $160,482110 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Synjardy Xr | $277 | $114,705110 claims |
| GSKTrelegy Ellipta | $184 | $101,82089 claims |
| PfizerEliquis | $93 | $85,08885 claims |
| AstraZenecaFarxiga, Symbicort | $551 | $70,96477 claims |
| MerckJanuvia, Janumet Xr | $147 | $65,49359 claims |
| AbbVieLinzess, Synthroid | $370 | $42,40183 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $125 | $37,33612 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $32 | $25,59721 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $24 | $21,31314 claims |
| BayerKerendia | $191 | $18,81417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Gastonia
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.